Antifungal therapy improves microbiome dynamics in inflammatory bowel disease
Nature Medicine, Published online: 01 September 2026; doi:10.1038/s41591-026-04616-y In an prospective observational study of patients with inflammatory bowel disease with oral thrush, the treatment of fluconazole (orogastrointestinal therapy), but not nystatin (oral therapy), led to intestinal mycobiome and microbiome alterations and improved disease activity at 8 weeks of follow-up.
We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.
